Full View

Precision targeted therapy for EGFR mutation‐positive NSCLC: Dilemmas and coping strategies

Y Meng, R Bai, J Cui - Thoracic Cancer, 2023 - Wiley Online Library
The most common driver gene mutation in patients with non‐small‐cell lung cancer
(NSCLC) is an epidermal growth factor receptor (EGFR) mutation. With the introduction of …
被引用次数：6 相关文章
[HTML] nih.gov

[HTML][HTML] Precision targeted therapy for EGFR mutation‐positive NSCLC: Dilemmas and coping strategies

Y Meng, R Bai, J Cui - Thoracic Cancer, 2023 - ncbi.nlm.nih.gov
The most common driver gene mutation in patients with non‐small‐cell lung cancer
(NSCLC) is an epidermal growth factor receptor (EGFR) mutation. With the introduction of …

Precision targeted therapy for EGFR mutation-positive NSCLC: Dilemmas and coping strategies

Y Meng, R Bai, J Cui - Thoracic Cancer, 2023 - search.proquest.com
The most common driver gene mutation in patients with non-small-cell lung cancer (NSCLC)
is an epidermal growth factor receptor (EGFR) mutation. With the introduction of EGFR …

Precision targeted therapy for EGFR mutation-positive NSCLC: Dilemmas and coping strategies

Y Meng, R Bai, J Cui - Thoracic cancer - pubmed.ncbi.nlm.nih.gov
The most common driver gene mutation in patients with non-small-cell lung cancer (NSCLC)
is an epidermal growth factor receptor (EGFR) mutation. With the introduction of EGFR …

Precision targeted therapy for EGFR mutation-positive NSCLC: Dilemmas and coping strategies.

Y Meng, R Bai, J Cui - Thoracic Cancer, 2023 - europepmc.org
The most common driver gene mutation in patients with non‐small‐cell lung cancer
(NSCLC) is an epidermal growth factor receptor (EGFR) mutation. With the introduction of …